Trial Profile
A study to assess the safety and tolerability of SB-681323 administered via the intravenous route
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Dilmapimod (Primary)
- Indications Atherosclerosis; Chronic obstructive pulmonary disease; Neuropathic pain; Rheumatoid arthritis
- Focus Adverse reactions
- 21 Mar 2007 New trial record.